# A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor

> **NCT05200650** · PHASE1 · RECRUITING · sponsor: **IntraGel Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **COMBINATION_PRODUCT:** TumoCure

## Key facts

- **NCT ID:** NCT05200650
- **Lead sponsor:** IntraGel Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-15
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200650, "A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05200650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*